Company: NKLR
Filing Date: 2025-11-10
Form Type: S-1
Source: 0001213900-25-108246
Chunk: 40

Company: Terra Innovatum Global N.V.
Filing Date: 2025-11-10
Form: S-1
Chunk 40
---
 debt, pay dividends, repurchase our securities, make certain investments, and
engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain
terms that are not favorable to us or our stockholders and members. If the needed financing is not available, or if the terms of financing
are less desirable than we expect, we may be required to delay, scale back or terminate some or all of our research and development programs.

Subsequent to the balance sheet date, we completed the Merger on October 9, 2025 (see “ Business Combination and Public Listing” below) and converted $5,690,000 in Bridge Loans into equity and warrants. While this development represents important steps toward improving the Company’s liquidity, management has not yet completed its going concern assessment due to the unavailability of our financial statements for the quarter ended September 30, 2025, and the absence of a finalized operating budget. We intend to update its going concern analysis in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which is expected to be filed on or about November 14, 2025.

We rely heavily on our intellectual property portfolio. Our ability to protect our patents and other intellectual property rights may be challenged and is not guaranteed. If we are unable to protect our intellectual property rights, our business and competitive position may be harmed.

We may not be able to prevent unauthorized use
of our intellectual property, which could harm our business and competitive position. We rely upon a combination of the intellectual
property protections afforded by patents, trademarks/service marks, copyrights and trade secret laws in the United States and other
jurisdictions, as well as commercial agreements such as confidentiality agreements, and license agreements to establish, maintain and
enforce rights associated with our MMRs and related proprietary technologies. These measures are aimed at preventing third parties from
using, practicing, selling, manufacturing, or otherwise commercially exploiting our MMRs and related technologies, which would erode
our competitive position in our market. Our success depends in large part on our ability to obtain and enforce patent protection for
our MMRs, as well as our ability to operate without infringing or violating the proprietary rights of others. We either own or have significant
license rights to certain intellectual property applicable to our MMRs, including patent rights and pending patent applications on the
same, and we will continue to file patent applications claiming new technologies directed to our MMR